A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

Summary

This trial is conducted in Asia. The aim of the trial is to compare the efficacy and safety of liraglutide 1.8 mg/day to liraglutide 0.9 mg/day in Japanese subjects with type 2 diabetes mellitus.

Timeline

Start

2015-07-21

Primary completion

2017-05-02

Completion

2017-11-09

Outcome

Met primary endpoint

registry analysis (superiority test); Liraglutide 1.8 mg vs Liraglutide 0.9 mg; p <0.0001; Treatment difference -0.40 (95% CI -0.55 to -0.24); ANCOVA NCT02505334 ↗

Drugs

Indications